Synergistic Abuse Deterrent Pharmaceutical Systems
Legal Citation
Summary of the Inventive Concept
Integrating abuse deterrent pharmaceutical compositions with AI, IoT, blockchain, and nanomaterials to create a more powerful system for preventing drug abuse and ensuring personalized drug delivery.
Background and Problem Solved
The original patent disclosed abuse deterrent pharmaceutical compositions that addressed opioid abuse. However, these compositions had limitations in tracking and controlling dosage, as well as ensuring personalized delivery. The new inventive concept addresses these limitations by synergistically combining the abuse deterrent pharmaceutical composition with distinct technologies to create a more robust system.
Detailed Description of the Inventive Concept
The new inventive concept comprises a synergistic combination of an abuse deterrent pharmaceutical composition and one or more of the following: AI-powered dosage tracking devices, blockchain-secured, IoT-enabled pharmaceutical compositions, pH-dependent solubility features, nanomaterial-based delivery systems, pH-modifying features, microchip-enabled tracking devices, and AI-powered genomic analysis tools. These components work together to monitor and control the release of the pharmaceutically active ingredient, track and verify dosage, and predict user response to the pharmaceutically active ingredient.
Novelty and Inventive Step
The new claims introduce a synergistic combination of distinct technologies that provides a more robust system for preventing drug abuse and ensuring personalized drug delivery. The integration of these technologies with the abuse deterrent pharmaceutical composition is new and non-obvious compared to the original patent.
Alternative Embodiments and Variations
Alternative embodiments may include integrating the abuse deterrent pharmaceutical composition with other technologies, such as machine learning algorithms, wearable devices, or cloud-based data analytics platforms. Variations may include using different types of nanomaterials, pH-modifying features, or genomic analysis tools.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of opioid abuse prevention and personalized drug delivery. Target markets may include pharmaceutical companies, healthcare providers, and government agencies focused on addressing the opioid epidemic.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/02 |
| A | A61 | A61K9/2009 |
| A | A61 | A61K9/2027 |
| A | A61 | A61K9/2077 |
| A | A61 | A61K31/5517 |
| A | A61 | A61K47/32 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical Formulation and Drug Delivery Systems, with expertise in abuse-deterrent pharmaceutical compositions, drug release mechanisms, and advanced drug delivery technologies
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in pharmaceutical sciences, chemical engineering, or related fields, possessing knowledge of drug formulation, controlled release technologies, and emerging pharmaceutical delivery methods
Obviousness Rationale
A PHOSITA would recognize that the PTD's integration of digital technologies with abuse-deterrent pharmaceutical compositions represents a predictable extension of existing abuse prevention strategies. The core principles of controlled drug release and abuse prevention from the source patent are directly augmented by emerging technologies like AI, IoT, and nanomaterials. These technological additions provide enhanced monitoring and control mechanisms that naturally build upon the foundational abuse-deterrent composition disclosed in the original patent.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,629 |
|---|---|
| Title | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
| Assignee(s) | Acurx Pharmaceuticals, Inc. |